Randomized Controlled Trial
Copyright ©The Author(s) 2023.
World J Gastroenterol. Aug 21, 2023; 29(31): 4783-4796
Published online Aug 21, 2023. doi: 10.3748/wjg.v29.i31.4783
Table 1 Poly(A)-specific ribonuclease shRNA target sequence
Target number
Target sequence
Human-PARN-1TATGACACAGCCTCTGAACA
Human-PARN-2TGGATACTAAATTGATGGCCA
Human-PARN-3CAACACATCCCTTGCGGAATT
Table 2 Primer sequences
Gene

Sequence (5’-3’)
Tm (°C)
GAPDHForward primerGAAAGCCTGCCGGTGACTAA60.32
Reverse primerGCCCAATACGACCAAATCAGAG59.39
PARNForward primerGCCGCGGAATTCGATTTTAAG58.63
Reverse primerATCGATGGCGAAGAAGTCGG60.25
Table 3 Relationship between poly(A)-specific ribonuclease expression and tumor characteristics in patients with esophageal cancer
Features
No. of patients
PARN expression
P value
Low
High
All patients914843
Age (yr)0.758
    < 65452322
    ≥ 65462521
Gender0.433
    Male734033
    Female18810
Tumor size0.110
    ≤ 5 cm462818
    > 5 cm351520
T Infiltrate0.680
    T0110
    T1312
    T21587
    T3392217
    T41046
Lymphatic metastasis (n)0.028a
    N0312011
    N118108
    N21147
    N3826
Stage0.336
    I321
    II301812
    III331419
    IV220
Lymphoid positive number0.164
    < 1432617
    ≥ 1462125
Grade0.516
    I743
    II492524
    III261610
Table 4 Relationship between poly(A)-specific ribonuclease expression and tumor characteristics (lymphatic metastasis) in patients with esophageal cancer (Spearman’s correlation coefficient for ranked data)


PARN
Lymphatic metastasis (N)Spearman correlation analysis0.269
Significance (two-tailed)0.027a
N68
Table 5 Immunohistochemistry scoring criteria
Score type
Score point
Score
Positive cell scoreNo positive signal0 (negative)
0% < the proportion of positive cells < 25%1
25% ≤ the proportion of positive cells < 50%2
50% ≤ the proportion of positive cells < 75%3
75% ≤ the proportion of positive cells4
Staining intensity score (the staining intensity of cytoplasm, membrane or nucleus)No signal color0 (negative)
Pale yellow1
Brown yellow2
Dark brown3